| Primary |
| Drug Use For Unknown Indication |
44.5% |
| Product Used For Unknown Indication |
7.3% |
| Hypertension |
5.7% |
| Ischaemic Heart Disease Prophylaxis |
4.3% |
| Prophylaxis |
3.9% |
| Atrial Fibrillation |
3.3% |
| Myocardial Infarction |
3.0% |
| Thrombosis Prophylaxis |
2.9% |
| Coronary Artery Disease |
2.5% |
| Antiplatelet Therapy |
2.5% |
| Anticoagulant Therapy |
2.5% |
| Pain |
2.2% |
| Suicide Attempt |
2.2% |
| Acute Coronary Syndrome |
2.2% |
| Headache |
2.2% |
| Stent Placement |
2.1% |
| Cardiovascular Event Prophylaxis |
1.9% |
| Cerebrovascular Accident Prophylaxis |
1.9% |
| Angina Pectoris |
1.6% |
| Diabetes Mellitus |
1.4% |
|
| Gastrointestinal Haemorrhage |
9.8% |
| Angioedema |
8.6% |
| Rectal Haemorrhage |
7.4% |
| Drug Toxicity |
6.9% |
| Vomiting |
6.8% |
| Haemorrhage |
6.6% |
| Melaena |
6.0% |
| Myocardial Infarction |
5.8% |
| Gastric Haemorrhage |
5.1% |
| Upper Gastrointestinal Haemorrhage |
3.8% |
| Urticaria |
3.6% |
| Tinnitus |
3.5% |
| Cerebral Haemorrhage |
3.5% |
| Therapeutic Agent Toxicity |
3.4% |
| Transient Ischaemic Attack |
3.4% |
| Gastric Ulcer |
3.4% |
| Thrombocytopenia |
3.2% |
| Rash |
3.1% |
| Haematochezia |
3.0% |
| Anaemia |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
21.5% |
| Drug Use For Unknown Indication |
20.3% |
| Hypertension |
10.5% |
| Atrial Fibrillation |
5.2% |
| Prophylaxis |
4.5% |
| Coronary Artery Disease |
4.2% |
| Myocardial Infarction |
3.6% |
| Acute Coronary Syndrome |
3.4% |
| Antiplatelet Therapy |
3.2% |
| Pain |
2.7% |
| Stent Placement |
2.7% |
| Type 2 Diabetes Mellitus |
2.5% |
| Thrombosis Prophylaxis |
2.4% |
| Diabetes Mellitus |
2.3% |
| Anticoagulant Therapy |
2.2% |
| Acute Myocardial Infarction |
2.1% |
| Depression |
1.9% |
| Hyperlipidaemia |
1.7% |
| Cerebrovascular Accident Prophylaxis |
1.6% |
| Angina Pectoris |
1.6% |
|
| Gastrointestinal Haemorrhage |
11.6% |
| Vomiting |
7.9% |
| Rectal Haemorrhage |
6.1% |
| Upper Gastrointestinal Haemorrhage |
6.1% |
| Haemorrhage |
5.4% |
| Drug Hypersensitivity |
5.3% |
| Myocardial Infarction |
5.2% |
| Hypotension |
5.2% |
| Completed Suicide |
4.7% |
| Weight Decreased |
4.7% |
| Renal Failure Acute |
4.5% |
| Melaena |
4.4% |
| Thrombocytopenia |
4.3% |
| Ventricular Tachycardia |
4.0% |
| Cerebral Haemorrhage |
3.8% |
| Thrombosis In Device |
3.8% |
| Death |
3.4% |
| Toxic Epidermal Necrolysis |
3.3% |
| International Normalised Ratio Increased |
3.2% |
| Haemoglobin Decreased |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.5% |
| Drug Use For Unknown Indication |
19.7% |
| Hypertension |
9.6% |
| Prophylaxis |
3.5% |
| Diabetes Mellitus |
3.4% |
| Blood Cholesterol Increased |
3.1% |
| Pain |
2.7% |
| Multiple Myeloma |
2.7% |
| Type 2 Diabetes Mellitus |
2.6% |
| Rheumatoid Arthritis |
2.6% |
| Depression |
2.0% |
| Atrial Fibrillation |
1.9% |
| Osteoporosis |
1.8% |
| Cardiac Disorder |
1.8% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Hyperlipidaemia |
1.2% |
| High Density Lipoprotein Decreased |
1.1% |
| Hypercholesterolaemia |
1.1% |
| Asthma |
1.1% |
|
| Flushing |
12.3% |
| Vomiting |
10.5% |
| Weight Decreased |
8.4% |
| Pruritus |
6.9% |
| Myocardial Infarction |
6.3% |
| Weight Increased |
4.9% |
| Death |
4.6% |
| Nausea |
4.3% |
| Paraesthesia |
4.0% |
| Pneumonia |
3.8% |
| Drug Ineffective |
3.8% |
| Renal Failure Acute |
3.7% |
| Urinary Tract Infection |
3.6% |
| Pain |
3.6% |
| Dyspnoea |
3.5% |
| Syncope |
3.4% |
| Rash |
3.3% |
| Pain In Extremity |
3.3% |
| Rhabdomyolysis |
2.9% |
| Tremor |
2.9% |
|
| Interacting |
| Product Used For Unknown Indication |
29.1% |
| Drug Use For Unknown Indication |
16.1% |
| Hypertension |
7.8% |
| Prophylaxis |
6.0% |
| Atrial Fibrillation |
4.6% |
| Acute Coronary Syndrome |
4.1% |
| Myocardial Infarction |
3.9% |
| Acute Myocardial Infarction |
3.8% |
| Periorbital Cellulitis |
3.3% |
| Pain |
2.8% |
| Depression |
2.4% |
| Angina Pectoris |
2.3% |
| Thrombosis Prophylaxis |
2.0% |
| Diabetes Mellitus |
1.9% |
| Type 2 Diabetes Mellitus |
1.8% |
| Antiplatelet Therapy |
1.7% |
| Anticoagulant Therapy |
1.7% |
| Deep Vein Thrombosis |
1.6% |
| Cardiac Failure |
1.6% |
| Chest Pain |
1.4% |
|
| Drug Interaction |
28.8% |
| Renal Failure Acute |
11.0% |
| International Normalised Ratio Increased |
6.8% |
| Gastrointestinal Haemorrhage |
6.4% |
| Tremor |
5.5% |
| Pyrexia |
5.1% |
| Melaena |
3.8% |
| Myocardial Infarction |
3.8% |
| Sudden Death |
3.8% |
| Dizziness |
2.5% |
| Multi-organ Failure |
2.5% |
| Retroperitoneal Haematoma |
2.5% |
| Vomiting |
2.5% |
| Haematemesis |
2.1% |
| Haemorrhage |
2.1% |
| Hyperglycaemia |
2.1% |
| Lower Gastrointestinal Haemorrhage |
2.1% |
| Nausea |
2.1% |
| Subdural Haemorrhage |
2.1% |
| Vitreous Haemorrhage |
2.1% |
|
